King's Research Portal

DOI:

[10.1016/j.mehy.2017.06.002](https://doi.org/10.1016/j.mehy.2017.06.002)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Abbasi, A. (2017). Are non-communicable diseases chronically communicable: a role for the human microbiota? *Medical Hypotheses*. <https://doi.org/10.1016/j.mehy.2017.06.002>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Are non-communicable diseases chronically communicable: a role for the human microbiota?

Ali Abbasi

PII: S0306-9877(17)30069-5

DOI: <http://dx.doi.org/10.1016/j.mehy.2017.06.002>

Reference: YMEHY 8582

To appear in: *Medical Hypotheses*

Received Date: 20 January 2017

Accepted Date: 1 June 2017

Please cite this article as: A. Abbasi, Are non-communicable diseases chronically communicable: a role for the human microbiota?, *Medical Hypotheses* (2017), doi: <http://dx.doi.org/10.1016/j.mehy.2017.06.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Are non-communicable diseases chronically communicable: a role for the human microbiota?

Ali Abbasi M.D., Ph.D.^{1,2}

1. Department of Primary Care & Public Health Sciences, King's College London, London, United Kingdom
2. Department of Epidemiology, University Medical Center Groningen, Groningen, the Netherlands

Correspondence to: Dr Ali Abbasi at the Department of Primary Care & Public Health Sciences, King's College London, 3rd Floor, Addison House, Guy's Campus, London, SE1 1UL, London, United Kingdom, or at ali.abbasi@kcl.ac.uk, tel: +44 (0)20 7848 6631.

There is increasing amount of information about the role of gut microbiome composition in communicable –or infectious diseases– and antibiotic resistance, but also how the human microbiota can be involved in chronic non-communicable diseases (NCDs) like diabetes and diabetes-related endophenotypes.(1) While much interest has recently been awakened that perturbations in gut microbiota are associated with the burden of antibiotic resistance(2), recent efforts investigating the potential causal effects or predictive value of information on the composition of microbiota, or their metabolites (e.g., Trimethylamine N-oxide (TMAO) in the circulation) or their functions (like changes in the gut-blood barrier (GBB) permeability) will open new avenues of research.(3-5)

Recently, experimental studies demonstrated how administration of *Akkermansia muciniphila*, one of the most abundant members of the human gut microbiota, to mice can prevent the development of obesity and associated complications.(3) In other words, pasteurization of *A. muciniphila* enhances its capacity to reduce insulin resistance and dyslipidemia in mice.(3) These findings were in line with previous evidence that microbiota transfer from adult male to female mice yielded in protection against diabetes development.(6) Moreover, there is evidence in human adults how taking metformin can influence the several microbial populations such as an increase in *A.muciniphila*.(7) As such evidence in human studies provides valuable insights into our understanding of metabolic disorders, it is time to re-think about the underlying host gene-environment and host-microbiome interactions to explore missing players and predictors for the prevention and treatment of non-communicable diseases.

So far, epidemiological observations or clinical trials have been mainly focused on genes, endophenotypes and the host gene- environment interactions.(8) Research studies in humans show that the host-microbiome communication is essential to maintain vital functions

of the healthy human over the life course.(1, 8) Therefore, the effect estimates (for human genes, biomarkers or interventions) obtained in the classical settings can be modified if one could take into account the transmission of human microbiota between people within a certain population.(1, 9, 10) Given the fact that microbiome traits are considered heritable and the trait associations tend to be small(8), complementary evidence from an integrative analysis of how the host gene-environment interaction can influence diversity and structure of the human microbiome and vice versa may find right matched pieces of the puzzle in these diseases.

Another aspect of research for microbiome-disease associations is to investigate whether additional information on the composition and structure of the human microbiota is of value to improve the risk prediction for NCDs. In this context, the performance of prediction models including classical risk factors and the utility of microbiome traits needs to be formally quantified using prognostic metrics and clinical reclassification. (11, 12). Few out of several studies on microbiota metabolites or functions have conducted a formal quantification to support predictive utility of these phenotypes for NCDs.(4, 5)

So, future lines of research need to focus on two hypotheses; human microbiota or a panel of microbiota-related phenotypes would improve risk prediction or be causally associated with NCDs. Such complementary strands of evidence may demonstrate if information about human microbiota can serve as prognostic markers for predicting clinical health outcomes and behavior; or as novel targets for new therapeutic and prevention strategies in clinical or public health practice.

Conflict of Interest Disclosures:

The author has no competing interests.

Funding/Support: This work was supported by the UK National Institutes for Health Research (NIHR) Health Services and Delivery Research programme. The views expressed are those of the author and not necessarily those of the UK National Health Service, NIHR, or the Department of Health (England).

Role of the Funder/Sponsor: The funders had no role in the preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References:

- [1] B.O. Schroeder and F. Backhed, Signals from the gut microbiota to distant organs in physiology and disease, *Nature medicine* **22** (2016), pp. 1079-1089.
- [2] E. van Nood, A. Vrieze, M. Nieuwdorp, *et al.*, Duodenal infusion of donor feces for recurrent *Clostridium difficile*, *The New England journal of medicine* **368** (2013), pp. 407-415.
- [3] H. Plovier, A. Everard, C. Druart, *et al.*, A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice, *Nature medicine* (2016).
- [4] M. Ufnal and K. Pham, The gut-blood barrier permeability - A new marker in cardiovascular and metabolic diseases?, *Medical hypotheses* **98** (2017), pp. 35-37.
- [5] X.S. Li, S. Obeid, R. Klingenberg, *et al.*, Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors, *European heart journal* (2017).
- [6] J.G. Markle, D.N. Frank, S. Mortin-Toth, *et al.*, Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity, *Science (New York, N.Y.)* **339** (2013), pp. 1084-1088.
- [7] J. de la Cuesta-Zuluaga, N.T. Mueller, V. Corrales-Agudelo, *et al.*, Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading *Akkermansia muciniphila* and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut, *Diabetes care* **40** (2017), pp. 54-62.
- [8] A.K. Benson, The gut microbiome-an emerging complex trait, *Nature genetics* **48** (2016), pp. 1301-1302.
- [9] G. Musso, R. Gambino and M. Cassader, Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?, *Diabetes care* **33** (2010), pp. 2277-2284.
- [10] H.J. Harmsen and M.C. de Goffau, The Human Gut Microbiota, *Advances in experimental medicine and biology* **902** (2016), pp. 95-108.
- [11] A. Abbasi, L.M. Peelen, E. Corpeleijn, *et al.*, Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study, *BMJ (Clinical research ed.)* **345** (2012), p. e5900.
- [12] K.G. Moons, D.G. Altman, J.B. Reitsma, *et al.*, Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration, *Ann Intern Med* **162** (2015), pp. W1-73.